



PRESS RELEASE



Embargo: March 3, 2008 at 8:30 AM (Brussels Time)

FOURNIER LABORATORIES IRELAND LTD AND LABORATOIRES FOURNIER SA FILED PATENT INFRINGEMENT ACTIONS AGAINST TEVA IN THE USA

Fournier Laboratories asserts intellectual property of TriCor® (fenofibrate) 145mg NFE

Fournier Laboratories Ireland Ltd (LFI) and Laboratoires Fournier S.A. (LFSA), wholly-owned subsidiaries of Solvay Pharmaceuticals, announced today that they have filed patent infringement court actions in the United States against Teva Pharmaceuticals.

In January 2008 Fournier was informed by Teva Pharmaceuticals that the latter had filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval of a generic version of TriCor® (fenofibrate) 145mg NFE tablets in the U.S. As part of its application process, Teva submitted a Paragraph IV certification as required by law.

Solvay Pharmaceuticals is fully committed to its fenofibrate franchise and will vigorously protect the intellectual property for this product against any infringement.

Solvay Pharmaceuticals is a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group. The company seeks to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardiometabolic, influenza vaccines, gastroenterology, and men's and women's health. Its 2007 sales were EUR 2.6 billion and it employs more than 9,000 people worldwide. For more information, visit www.solvaypharmaceuticals.com.

SOLVAY is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs more than 28,000 people in 50 countries. In 2007, its consolidated sales amounted to EUR 9.6 billion, generated by its three sectors of activity: Chemicals, Plastics and Pharmaceuticals. Solvay (NYSE Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR) is listed on the NYSE Euronext stock exchange in Brussels. Details are available at www.solvay.com

For further information please contact:

MARTIAL TARDY

Corporate Press Officer

SOLVAY S.A.

Phone: 32 2 509 72 30

E-mail: martial.tardy@solvay.com

Internet: www.solvaypress.com

PATRICK VERELST

Investor Relations

SOLVAY S.A.

Phone: 32 2 509 72 43

E-mail: patrick.verelst@solvay.com

Internet: www.solvay-investors.com

WERNER VAN DEN EYNDE, MD

Pharmaceutical Communications

SOLVAY PHARMACEUTICALS S.A.

Tel: +32 2 509 62 27

E-mail: werner.vandeneynde@solvay.com

Internet: www.solvaypharmaceuticals.com

Ce communiqué de presse est également disponible en français – Dit persbericht is ook in het Nederlands beschikbaar